FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

ı	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burder	า								
	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Bonick Martin (Last) (First) (Middle) 4000 MERIDIAN BOULEVARD						Susuer Name and Ticker or Trading Symbol COMMUNITY HEALTH SYSTEMS INC [CYH] 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2016								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Division President							
(Street) FRANKL (City)			37067					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Trans Date					nsactio				3. Transaction Code (Instr. 8) 4. Securities A Disposed Of (I			Acquired (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								(World in Day) Tear)		v	Amount	nount (A) or (D)									
Common S	Stock		01/20	1/2016			М		35,000	A	\$0.00	63,265		D							
Common S	Stock	01/20	/2016			М		6,667	A	\$0.00	69,932		D								
Common Stock 03/01							1/2016		F		9,789	D	\$15.43	60,143			D				
											sed of, or onvertible			wned							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day	Date, Trans		action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerci Expiration Da (Month/Day/Yo		ate of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported	ve Ores For ally Origing (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	le V (A)		(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares		Transacti (Instr. 4)	ion(s)					
Performance Based Restricted	\$0.00	03/01/2016			M ⁽¹⁾			35,000	03/01/2010		02/28/2025	Common Stock	35,000	\$0.00	0		D				
Performance Based Restricted	\$0.00	03/01/2016			M ⁽²⁾			6,667	(2)		(2)	Common Stock	6,667	\$0.00	0		D				
Performance Based Restricted	\$0.00	03/01/2016			A		35,000	5,000		2017 ⁽³⁾	02/28/2026	Common Stock	35,000	\$15.43	35,00	00	D				
Stock Options (Right to	\$16.66								12/14	/2012	12/13/2021	Common Stock	1,000		1,00	0	D				

Explanation of Responses:

- 1. The performance objectives governing these shares of Performance Based Restricted Stock have been met, and, accordingly, these shares will now be reported in Table 1 as directly owned shares of Restricted Stock. The time-vesting restrictions lapse in 1/3 increments on the first, second and third anniversary of the date of grant.
- 2. Pursuant to the terms governing the award, the Company has achieved the cost savings ("synergies") from the Health Management Associates, Inc. ("HMA") merger transaction that were required to be achieved during the first two years following the HMA merger transaction, and, accordingly, the performance-based restrictions on the remaining portion of the award have lapsed as of the second anniversary of the date of grant. All such shares will now be reported on Table 1 as directly owned shares of Restricted Stock. There is also a time-vesting element. The time-vesting restrictions lapse in equal installments on the second and third anniversary of the date of grant.
- 3. Each performance based restricted share represents a contingent right to receive one share of CYH common stock. There are two elements to the lapsing of the performance-based restriction; first, the Company must achieve specified targeted amount of adjusted EBITDA or net revenue from continuing operations, and if the performance objective is met, the time-vesting restrictions will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. If the performance objectives are not met, the shares will be forfeited.

Remarks:

Christopher G. Cobb, Attorney in Fact for Martin Bonick

03/02/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.